Breast Cancer Research and Treatment **61:** 271–272, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Authors Index, Volume 61

Adachi I 131 145
Akechi T 131 145
Albérini JL 21
Andersen J 103
Andersson L 197
Andersson M 103
Ando M 131
Ansai Y 261
Arnal M 13
Avril A 151

Bastholt L 103
Berglund G 121
Bernstein J 79
Bharaj B 111
Blankenstein MA 197
Body J-J 59
Bondesson L 121
Bonichon F 151
Borbas C 171
Bourguet P 21
Braccia I 79
Brunet-Lecomte P 13

Carlson DL 161
Choong PFM 1
Christensen IJ 103
Clinchy B 217
Cloirec JL 21
Coindre J-M 151
Cropley J 79
Cutler ML 69

Dazord L 21
Denzler B 21
Devillers A 21
Diallo I 183
Diamandis EP 111
Dombernowsky P 103
Dougherty GW 69
Drumea KC 79
Durand M 151

Eck-Enriquez K 229
Edgerton SM 33

Fargeot P 13
Field CL 1
Fisher JL 1
Franco N 13

Garne JP 121
Gazdar A 217
Giai M 111
Gordon B 217
Green S 79
Groshen SG 249
Guadagnoli E 171
Gurwitz JH 171

Harris TL 1
Hellmén E 197
Henderson MA 1
Hill SM 229
Hino K 261
Hoffman BR 111
Horenstein MG 161
Howard GCW 139

Janzon L 121
Jeng J 87
Jong R de 21

Kakudo K 211
Kamby C 103
Kaplan E 79
Katsumata N 131 145
Kiefer TL 229
Kokawa Y 211
Krupnik A 79
Kugaya A 145

Lê MG 183
Lacroix M 59
Laissue J 21
Lara CT de 151
Levesque MA 111
Levine E 79
Liu S 33
Lizard-Nacol S 13

MacGrogan G 151
Malina J 121
Mandell L 79
Manjer J 121
Marie PJ 59
Markland FS 249
Mascarel I de 151
Mauriac L 151
Meunier B 21
Miller WR 139
Møller KA 103
Moller M 197
Moore II DH 33
Mori I 211
Morris N 171
Mouridsen HT 103
Munkholm P 103

Nakamura M 211
Nakamura Y 211
Narabayashi M 131

Obropta J 79
Okamura H 131 145
Osborne MP 161

Parrish C 249
Phillips HA 139
Picot V 151
Ponchio L 241
Prada GADa 241

Rabinovsky R 217
Reubi JC 21
Richters V 249
Riedinger J-M 13
Robustelli della Cuna FS 241
Robustelli della Cuna G 241

Rose C 103
Rosenstein BS 79
Rubino C 183

Sakurai T 211
Scorilas A 111
Shamsaldin A 183
Shan L 211
Shank B 79
Shapiro CL 171
Sherwin RP 249
Shi Q 33
Shimizu T 261
Simple TLe 21
Soslow RA 161
Soumerai SB 171
Spriggs LL 229
Sutherland DJA 111
Suzuma T 211
Takashima S 145
Tamaki T 211
Tang W 211
Tass P 21
Tauchi K 261
Thor AD 33
Trojani M 151
Tsao SW 45
Tsao-Wei D 249
Tsukada K 261

Ucci G 241
Uchitomi Y 131 145
Umemura T 211
Utsunomiya H 211

Vasaturo F 69
Vathaire F de 183
Vitetta ES 217
Wang TTY 87
Watanabe T 131 145
Weeks JC 171
Westermark B 197
Wong YC 45

Xie B 45

Yamamoto N 145
Yang Q-F 211
Yefenof E 217
Yoshimura G 211

Zambelli A 241
Zhou H 1
Zhou Q 249

Breast Cancer Research and Treatment **61:** 273–275, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 61

adhesion
  and the influence of contortrostatin on breast cancer progression 249-260
adjustment disorders
  following first recurrence of breast cancer 131-137
advanced breast cancer
  enhancement of *mdr1* gene expression 13-20
  patients undergoing salvage treatment 241-247
agar growth
  of MCF7 breast cancer cells 69-78
aminoglutethimide
  in combined endocrine treatment of breast cancer 103-110
androgen receptor
  expression of Bcl-2 and Bax in hormonal mammary carcinogenesis 45-57
  PSA gene ARE polymorphism in breast cancer patients 111-119
angiogenesis
  and the inhibition of breast cancer progression by contortrostatin 249-260
  antibody to platelet/endothelial cell adhesion molecule to evaluate MVD and the predication of node status intravenous DSA 261-269
apoptosis
  Bcl-2 and Bax expression in hormonal mammary carcinogenesis 45-57
  induced by melatonin and retinoids 229-239
ataxia telangiectasia
  and the risk of breast cancer 79-85
ATM
  heterozygosity and breast cancer 79-85
axillary lymphnode metastasis
  predication by untravenous digital subtraction angiography 261-269
  somatostatin receptor scintigraphy used in prospective analysis 21-32

Bax
  expression in hormonal mammary carcinogenesis 45-57
Bcl-2
  correlating with in vitro chemosensivity 211-216
  expression in hormonal mammary carcinogenesis 45-57
bone
  metastases in osseous breast cancer and the uPA system 1-12
breast cancer cells
  and bone proteins 59-67
breast conserving surgery
  as a treatment option for medical opinion leaders 171-175
breast ductal carcinoma *in situ* (DCIS) application of the Van Nuys prognostic index 151-159

cell cycle
  markers in lobular carcinomas 161-170
cell lines
  from mesenchymal canine mammary tumour 197-210
chemosensivity
  and the expression of Bcl-2 211-216
chemotherapy
  its role in the increased risk of second cancers after breast cancer 183-195
clinical trial
  of patients' understanding and survival potential 145-150
cohort study
  confirming the increased risk of second cancers after breast cancer 183-195
collagen
  degradation in tumor-induced osteolysis related to metastizing breast cancer cells 59-67
continuous infusion chemotherapy
  in pretreated breast cancer patients 241-247

disintegrin
  contrortrostatin inhibiting breast cancer progression 249-260
dog/canine
  mesenchymal mammary tumour cell lines 197-210
ductal
  carcinomas and the comparison of cell cycle markers in lobular carcinomas 161-170

Erk
activation in MCF7 breast cancer cells 69-78
17β-estradiol
regulating mRNA in human breast cancer cells 87-96
ex-smokers
related to breast cancer incidence 121-129

first recurrence
of breast cancer followed by psychological distress 131-137
fluoxymesterone
in a combined endocrine treatment of breast cancer 103-110

HDRA
and the *in vitro* chemosensivity of Bcl-2 211-216
Her-2/neu
-overexpressing tumor cell lines in SCID mice 217-228
histologic subtypes
of breast carcinomas and their cell cycle markers 161-170
hospital practices
and medical opinion leaders 171-175

informed consent
for metastatic breast cancer patients 145-150
^{111}In-pentetreotide
used in somatostatin receptor scintigraphy for breast cancer 21-32
intravenous digital subtraction angiography
predication of node status 261-269
invasion
prevented by contrortrostatin in breast cancer 249-260
in-vivo tumor models
of *HER-2/neu*-overexpressing tumor cell lines in SCID mice 217-228
isoforms
regulation of TRAIL-R2 in human breast cancer cells 87-96

Jun kinase
activation in MCF7 breast cancer cells 69-78

lobular
and ductal carcinomas and a comparison of cell cycle markers 161-170
local recurrence rate
of the VNPI in a series of 367 ductal carcinomas *in situ* 151-159

major depressive disorder
following first recurrence of breast cancer 131-137
mammary gland
affected by tumours in dogs 197-210
mastectomy
as a treatment option for medical opinion leaders 171-175
matrix metalloproteinases
their role in tumor-induced osteolysis related to metastizing breast cancer cells 59-67
MCF7
cells treated with DNA damaging agents in human breast cancer 87-96
expression of *Rsu-1* in breast cancer cells 69-78
mdr1 gene expression
in normal and tumoral breast tissues 13-20
melatonin
and retinoids inducing breast cancer cell apoptosis 229-239
mesenchymal tumour
in dogs and humans 197-210
metastases
of human and the HER-2/neu-overexpressing tumor cell lines in SCID mice 217-228
reduced by contortrostatin and inhibiting breast cancer progression 249-260
uPA in osseous breast cancer 1-12
metastatic breast cancer
combined endocrine treatment of elderly postmenopausal patients 103-110
clinical trial of patient's understanding and survival potential 145-150
microvascular density
predication of node status by intravenous digital subtraction angiography 261-269
mRNA
TRAIL-R2 isoforms regulation in human breast cancer cells 87-96
mutation
of p53 and nipple aspirate fluids from patients with breast cancer 139-143
PSA gene ARE polymorphism in breast cancer patients 111-119
screening of *ATM* gene in breast cancer patients 79-85

neovascularization of lymph nodes
predication of node status by intravenous digital subtraction angiography 261-269
nipple aspirate fluid
and p53 mutations from patients with breast cancer 139-143
normal tissues
and the enhancement of *mdr1* gene expression in advanced breast cancer patients 13-20

oestrogen receptor
and the expression of Bcl-2 and Bax in hormonal mammary carcinogenesis 45-57
OPN
mRNA expression detected in osseous breast cancer metastases 1-12
osteoblasts
protein production related to metastizing breast cancer cells 59-67

$p21^{WAF/CIP}$
elevation due to expression of *Rsu-1* in MCF7 breast cancer cells 69-78
$p21^{WAF1/CIP1}$
expression in breast cancers and associations with p53 33-43
p53
immunopositivity in breast cancers and the expression of $p21^{WAF1/CIP1}$ 33-43
mutations and nipple aspirate fluids from patients with breast cancer 139-143
percentage of positive blocks
as predictor for local recurrence in the VPNI group 151-159
physician behavior
and medical opinion leaders 171-175
plasmin
in relation to breast cancer cells and bone proteins 59-67
polymorphism
susceptibility in breast cancer patients 111-119
postmenopausal
patients treated with combined endocrine therapy 103-110
prognosis
relevance of PSA gene ARE polymorphism in breast cancer patients 111-119
with p21 immunohistochemical analyses of breast cancer patients 33-43
proteinase inhibitors
and their role in breast cancer cells 59-67
psychological distress
following first recurrence of breast cancer 131-137

radiotherapy
its role in the increased risk of second cancers after breast cancer 183-195
receptor autoradiography
analysis with SS-R in breast tumors 21-32
retinoic acid
and melatonin inducing breast cancer cell apoptosis 229-239
Rho kinase
activation in MCF7 breast cancer cells 69-78
Rsu-1
expression in MCF7 breast cancer cells 69-78
RT-PCR
used to investigate *mdr1* gene expression in advanced breast cancer 13-20

SCID mice
HER-2/neu-overexpressing tumor cell lines in SCID mice 217-228
second primary cancer
increased risk after breast cancer 183-195
smoking
cessation in relation to breast cancer incidence 121-129
soluble Her-2
cell lines in SCID mice and the growth of metastasis of human 217-228
somatostatin receptors
in breast cancer and axillary lymph nodes 21-32
stem cell
developing mesenchymal canine mammary tumour 197-210

tamoxifen
combined endocrine treatment of elderly patients 103-110
tobacco
breast cancer incidence in relation to smoking cessation 121-129
TRAIL-R2
regulation of isoforms in human breast cancer cells 87-96
tumor-induced osteolysis
caused by metastasizing breast cancer cells 59-67

uPA
in osseous breast cancer metastases 1-12